Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Polycythemia Vera 6Thrombocythemia, Essential 5Carcinoma, Hepatocellular 4Neoplasms 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Philadelphia Chromosome 2Neoplasm Metastasis 2Myeloproliferative Disorders 2Leukemia 2Hepatitis C, Chronic 2Carcinoma, Squamous Cell 2Skin Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neoplasm, Residual 1Melanoma 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Influenza, Human 1Infections 1Hepatitis C 1Hepatitis B, Chronic 1Hemangiosarcoma 1Colonic Neoplasms 1Breast Neoplasms, Male 1Breast Neoplasms 1Brain Neoplasms 1Blast Crisis 1

Interventions

Ribavirin 4ledipasvir, sofosbuvir drug combination 2Chromatography, High Pressure Liquid 2tremelimumab 1telaprevir 1sofosbuvir-velpatasvir drug combination 1pembrolizumab 1peginterferon alfa-2a 1ledipasvir 1grazoprevir 1elbasvir-grazoprevir drug combination 1elbasvir 1Sofosbuvir 1Rapid Diagnostic Tests 1Patient Navigation 1Introns 1Infliximab 1Immunoenzyme Techniques 1Hypothermia, Induced 1Enzyme-Linked Immunosorbent Assay 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hepatitis C × peginterferon alfa-2a × Clear all
NCT01821963 2020-09-24

Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)

M.D. Anderson Cancer Center

Phase 3 Terminated
1 enrolled 3 charts
Gastrointestinal

Hepatitis C, Carcinoma, Hepatocellular, Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡